AsianScientist (Mar. 23, 2016) – Huawei, a leading global information and communications technology provider, and WuXi AppTec, the global open-access R&D platform, have announced the signing of a strategic framework agreement to support the China Precision Medicine Initiative (China PMI) through the creation of a precision medicine cloud platform.
The agreement builds on Huawei’s capabilities and reach in cloud infrastructure, and the genomics and precision medicine expertise of WuXi NextCODE, the genomic information and precision medicine subsidiary of WuXi AppTec.
Cloud computing is the way genomic big data will be used to drive precision medicine innovation and deliver better healthcare in a cost-efficient manner. Huawei’s cloud platform serves 50,000 customers across China, with data centers in 15 cities. WuXi NextCODE genomics technology powers population genomics and large-scale precision medicine efforts in the UK, Qatar, US and China.
“This partnership is a win-win-win—for our companies and for the patients that will benefit from the vision of the China PMI,” said Hannes Smarason, COO of WuXi NextCODE.
“Our technology underpins genome-driven medicine at Genomics England, the Qatar Genome Project, Boston Children’s Hospital and Harvard Medical School, and in China at Fudan University. We are thrilled to be deploying it with Huawei across China, a key part of our strategy to advance a global standard for turning the genome into better health.”
Source: WuXi Apptec.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.